Advanced cellular therapy for knee osteoarthritis utilizing UC-MSC exosomes that suppress inflammatory pathways, inhibit NLRP3-mediated synovial inflammation, and promote cartilage repair without invasive surgery.
Clinical Rationale
Multiple active Phase I/II trials investigate intra-articular UC-MSC exosomes for knee osteoarthritis with endpoints focused on safety and functional improvement. UC-MSCs inhibit NLRP3-mediated synovial inflammation in early-stage disease, addressing underlying pathology rather than symptomatic management. Our approach promotes cartilage regeneration and reduces inflammatory mediators through targeted paracrine signaling.